

Webinar Presentation

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) delivering and developing new treatments for major mental health challenges and select neurological conditions, is pleased to announce its participation in the

ShareCafe Small Cap "Hidden Gems" Webinar, to be held Friday 2nd of February 2024 from 12:30pm AEDT/ 9:30am AWST.

Emyria’s Managing Director, Dr. Michael Winlo will provide an overview of the Company, which is developing and delivering new treatments for mental health and select neurological conditions through a unique business model combining direct care & drug development.

This webinar can be viewed live via Zoom and will provide viewers the opportunity to hear from, and engage with, a range of ASX-listed leading micro/mid cap companies.

To access further details of the event and to register at no cost, please copy and paste the following link into your internet browser:

https://us02web.zoom.us/webinar/register/WN_Xb_tWO_eR6yXkSyaMmqhrA

A copy of the presentation is attached to this announcement and a recorded copy of the webinar will be made available following the event.

FOR FURTHER INFORMATION

Managing Director
Michael Winlo
+61 (0) 8 6559 2800
mwinlo@emyria.com

Media Contact
Haley Chartres
+61 (0) 423 139 163
haley@hck.digital

Corporate Advisor
Sufian Ahmed
+61 (0) 412 316 162
info@62capital.com.au

For personal use only

For personal use only

emyria

(ASX:EMD)

Delivering & developing new treatments to improve mental health

02 February 2024
ShareCafe Presentation



DISCLAIMER to presentation

This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any jurisdiction. This presentation contains general information only and does not consider the investment objectives, financial situation and needs of individual investors. Investors should make their own independent assessment of the information in this presentation and obtain their own independent advice from a qualified financial adviser having regard to their personal objectives, financial situation and needs before taking any action. No representation or warranty, express or implied, is made as to the accuracy, completeness, reliability or adequacy of any statements, estimates, opinions or other information, or the reasonableness of any assumption or other statement, contained in this presentation. Nor is any representation or warranty (express or implied) given as to the accuracy, completeness, likelihood of achievement or reasonableness of any forecasts, prospective statements or returns contained in this presentation. Such forecasts, prospective statements or returns are by their nature subject to significant uncertainties and contingencies, many of which are outside the control of Emyria. To the maximum extent permitted by law, Emyria and its related bodies corporate, directors, officers, employees, advisers and agents disclaim all liability and responsibility (including without limitation any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything contained in, or omitted from, this presentation. An investment in Emyria securities should be considered speculative and is subject to investment and other known and unknown risks, some of which are beyond the control of Emyria. Emyria does not guarantee any rate of return or the absolute or relative investment performance of Emyria securities. The distribution of this presentation including in jurisdictions outside Australia, may be restricted by law. Any person who receives this presentation must seek advice on and observe any such restrictions.

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of Emyria and certain of the plans and objectives of Emyria with respect to these items. These forward-looking statements are not historical facts but rather are based on Emyria's current expectations, estimates and projections about the industry in which Emyria operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Emyria, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Emyria cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Emyria only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Emyria will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. These effects are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision.

EMYRIA | ONLY ASX-LISTED COMPANY EVALUATING DRUG-ASSISTED THERAPIES

Our goal is to become a global leader in the delivery & development of new treatments for major mental health challenges and select neurological conditions

For personal use only

MENTAL HEALTH FOCUS

Starting with **PTSD** - affecting ~1M Australians.

DRUG-ASSISTED THERAPIES

First to trial **MDMA-assisted therapy** (under TGA guidelines) in a community clinic.

ACTIVE PATIENT CARE

We have cared for over **20,000** patients. Today's clinical billings ~**\$1M/qtr.**

STRONG IP FROM CLINICAL DATA

Proprietary clinical data supports robust IP and our **innovation pipeline.**

WORLD-CLASS TEAM & PARTNERS

Valued partners like the **NIH** & the University of Western Australia support our research programs.

WHY START WITH DRUG-ASSISTED THERAPIES FOR MENTAL HEALTH?

We Have A Growing Mental Health Burden

1 in 5 Australian adults had a mental disorder last 12m ¹

1 in 3 Australian psychologists have closed books ²

Drug-Assisted Therapies Are Showing Promise & Attracting Investment ^{3,4,5}

THE WALL STREET JOURNAL.

Ecstasy-for-Medicine Advocate Raises \$100 Million

Series A funding raises more than \$100 million for MAPS affiliate amid a flurry of deals by competitors

By Matt Wirz [Follow](#)
Updated Jan. 5, 2024 at 8:54 am ET

[Share](#) [Resize](#) [Listen \(2 min\)](#)

But, only Australia Has Rescheduled These Treatments ⁶

[Home](#) > [News and Community](#) > [Media releases](#)

Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists

Published: 3 February 2023

[Listen](#) [Print](#) [Share](#)

From 1 July this year, medicines containing the psychedelic substances psilocybin and MDMA (3,4-methylenedioxy-methamphetamine) can be prescribed by specifically authorised psychiatrists for the treatment of certain mental health conditions.

SOURCES:

1. BlackDog Institute Pre-Budget Submission January 2023. Note: BlackDog Institute has not provided its consent to be named in this Presentation
2. <https://psychology.org.au/for-members/news-and-updates/news/2022/australians-need-psychological-help-more-than-ever>
3. Mitchell, J.M., et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. *Nat Med* 27, 1025–1033 (2021)
4. Mitchell, J.M., et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. *Nat Med* (2023). <https://doi.org/10.1038/s41591-023-02565-4>
5. <https://www.wsj.com/finance/legalization-advocate-maps-raises-money-for-pharmaceutical-psychedelics-a0f1ff94>
6. <https://www.tga.gov.au/products/unapproved-therapeutic-goods/mdma-and-psilocybin>

For personal use only

For personal use only

**TO EVALUATE THE POTENTIAL OF
INTENSIVE PSYCHOTHERAPY
SUPPORTED BY MEDICATION...**

**WE BELIEVE COMPANIES WHO ARE EXPERTS IN
THERAPY DELIVERY AND DEVELOPMENT WILL
HAVE A MAJOR ADVANTAGE**



EMYRIA HAS MADE SIGNIFICANT PROGRESS LAST 24 MONTHS

Emyria's growth strategy

For personal use only

BUILD CAPABILITY

- ✓ Fit-for-purpose **facilities** ¹
- ✓ **20+** trained clinicians ²
- ✓ Robust data capture systems ³
- ✓ **20,000** patients to date
- ✓ Commenced **MDMA-assisted** therapy trials ⁴

2021-2023



DEMONSTRATE COMMERCIAL VIABILITY

- ✓ **Authorised Prescribers** ⁵
- ✓ **\$1m** / qtr billings (today) ⁶
- Service expansion underway
- Engaging payers

2024



SCALE VIA INNOVATION & PARTNERSHIPS



- Seek growth opportunities via partnerships
- Leverage proprietary IP and data to advance novel **care models** and **drug treatments**

FUTURE



SOURCES:

1. See ASX release 13 September 2023
2. See ASX release 21 September 2023
3. See ASX release 07 October 2021
4. See ASX release 09 October 2023

5. See ASX release 10 January 2024
6. See Quarterly Report for 31 Dec 2023

For personal use only

WHY ARE WE STARTING WITH POST-TRAUMATIC STRESS DISORDER?

PTSD is a chronic, debilitating health disorder that can occur following a traumatic event

~1,000,000
AUSTRALIANS

6% of all adults ¹



~500,000

50% inadequate treatment response ²
& associated with significant
socioeconomic burden

**MDMA-ASSISTED
THERAPY IS SHOWING
PROMISE ³**

71.2% of MDMA-AT
participants no longer met
PTSD criteria, compared to
47.6% in the placebo group.

NOTE: The safety and efficacy of
MDMA-assisted therapy is still under
investigation. It does not work for everyone
and carries risks even in therapeutic settings
(see Slide 2)

**EMYRIA HAS
COMMENCED
MDMA-AT TRIALS ⁴**

At our specialist psychological trauma
treatment centre



SOURCES:

1. See ASX presentation 06 September 2023

2. Davis LL, Schein J, Cloutier M, et al. The economic burden of posttraumatic stress disorder in the United States from a societal perspective. J Clin Psychiatry. 2022;83(3):21m14116

3. Mitchell, J.M., et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med (2023). <https://doi.org/10.1038/s41591-023-02565-4>

4. See ASX release 09 October 2023

For personal use only


WHAT IS MDMA-ASSISTED THERAPY (MDMA-AT)?

Psychotherapy while under the influence of medical-grade MDMA to enhance the therapeutic process

MDMA




PSYCHOTHERAPY



MDMA (3,4-methylenedioxyamphetamine or "ecstasy")

MDMA produces feelings of emotional connection, openness and fear extinction



Supportive intensive, trauma-informed psychotherapy is believed to be crucial to therapeutic benefit

Proposed Benefits with Skilled Therapy

MDMA-AT is thought to assist patients to access traumatic memories with reduced distress.


Improved feelings of trust and wellbeing while under the influence of medication can support communication and strengthen the therapeutic alliance between patient and therapist.

Risks & Exclusions


Patients with cardiovascular or psychotic disease are generally excluded. Main side effects can include anxiety, restlessness, fatigue, jaw-clenching, headache and transient increases in blood pressure and / or heart rate - all of which are closely monitored.¹

MDMA-AT SHOWING PROMISE FOR PTSD | TWO PHASE 3 TRIALS COMPLETED ^{1,2} (MAPP1 & MAPP2)

Improves symptoms



Improves function





Key benefits after 3 treatment sessions

86.5% of MDMA-AT participants reported improvement, compared to 69% in placebo group.

Further enhancements reported in various life areas, including familial, social, and professional aspects.

Risks associated with MDMA-AT are set out in Slide 2.




MDMA-AT significantly reduced PTSD symptoms, as shown by the change in CAPS-5 total severity score from baseline to 18 weeks after baseline

MDMA-AT significantly improved quality of life, as shown by the change in Sheehan Disability Scale score from baseline to 18 weeks after baseline

For personal use only

MDMA-AT COSTS¹ vs STANDARD OF CARE^{2,3}

If Phase 3 clinical trial remission rates can be achieved in real world settings, MDMA-AT is cost effective for PTSD



Sources:

1. Costs are estimated based on estimates of direct clinician time required to delivery program

2. Standard of care costs based on conversations with clinical specialists. WA East Metropolitan Health Service reported Specialised Mental Health Care Days average cost of \$2,156 per day in FY 2022 / 2023 (<https://annualreport.emhs.health.wa.gov.au/key-performance-indicators/browse-kpis/average-cost-per-bed-day-in-specialised-mental-health-inpatient-services/>)

3. Marseille E, et al. The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD. PLoS One. 2020 Oct 14;15(10):e0239997. doi: 10.1371/journal.pone.0239997. PMID: 33052965; PMCID: PMC7556534.

WHY EMYRIA IS STARTING WITH **MDMA-ASSISTED THERAPY** ('MDMA-AT') FOR PTSD:

For personal use only

1

PTSD NEEDS NEW TREATMENTS

PTSD affects **6%** of all Australians (~1M people) ¹
60% more prevalent in **first-responders** ²
50% of patients develop **treatment resistance** ³

2

MDMA-AT SHOWS PROMISE IN CLINICAL TRIALS - RISKS ASSOCIATED WITH THE USE OF MDMA ARE SET OUT IN SLIDE 2

After 3 treatments, **70%** of participants no longer met criteria for PTSD (*compared to ~48% in placebo group*). Results replicated across two, Phase 3 trials ^{4,5}

3

MDMA-AT IS COST EFFECTIVE

us\$132.9 million expected to be saved over 30 years per 1,000 treatments ⁶

4

EMYRIA KNOWS HOW TO DELIVER INNOVATIVE SERVICES

We've cared for **20,000+** and our team is experienced in providing services compliant with strict regulatory standards

5

EMYRIA HAS A BUSINESS MODEL FOR GROWTH

\$1m / quarter current clinical billings, and growing, supports clinic expansion and novel drug development ⁷

SOURCES:






1. <https://www.phoenixaustralia.org/news/ptsd-awareness-day-2022/>
2. Bryant RA. The nature of PTSD in treatment-seeking first responders. Eur J Psychotraumatol. 2022 Jan 26;13(1):2011602.
3. Committee on the Assessment of Ongoing Efforts in the Treatment of Posttraumatic Stress Disorder; Board on the Health of Select Populations; Institute of Medicine. Washington (DC): National Academies Press (US); 2014 Jun 17.

4. Mitchell, J.M., et al. MDMA-assisted therapy for severe PTSD: Nat Med 27, 1025–1033 (2021)
5. Mitchell, J.M., et al. MDMA-assisted therapy for moderate to severe PTSD: Nat Med (2023). <https://doi.org/10.1038/s41591-023-02565-4>
6. Marseille E., et al. Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the US Findings from a phase 3 trial. PLoS One. 2022 Feb 25;17(2):e0263252. doi: 10.1371/journal.pone.0263252
7. See September Quarter 4C, 2023

INNOVATIVE, PREMIUM CLINICAL SERVICES CAN DO WELL

Our industry peers

For personal use only

COMPANY	SECTOR	VALUATION or (REVENUES)
 Oak St. Health	A US health care network of primary care centers for older adults with Medicare	USD\$10.7B (acquired by CVS) ¹
 Healthia Your local healthcare leader	An integrated allied healthcare organisation with networks of optometry, podiatry, and physiotherapy clinics	A\$260M (acquired by Pacific Equity Partners) ²
 Sonic HealthPlus SONIC CLINICAL SERVICES	Occupational medicine and general practice services	(Revenues over A\$200M / year) ³
 one medical	A US chain of primary healthcare clinics	USD\$3.9B ⁴ (acquired by Amazon)
 cityblock	A US health care network focussed on Medicare and Medicaid	Has raised over USD\$800M ⁵

SOURCES:

- <https://www.cvshealth.com/news/company-news/cvs-health-completes-acquisition-of-oak-street-health.html>
- <https://www.afr.com/street-talk/moelis-tapped-for-pep-s-1-80-a-share-bid-for-healthia-20230831-p5e0ux>
- https://investors.sonichealthcare.com/FormBuilder/_Resource/_module/T8Ln_c4ibUqyFnnNe9zNRA/docs/Reports/AR/SHL_Annual_Report_2023.pdf
- <https://press.aboutamazon.com/2022/7/amazon-and-one-medical-sign-an-agreement-for-amazon-to-acquire-one-medical>
- <https://www.cbinsights.com/company/cityblock-health/financials>

EMYRIA | CORPORATE OVERVIEW

Strategic investment from leading life science institutional investors

ASX: EMD TRADING INFORMATION

Share Price	A\$0.054¹
6-Month low / high	A\$0.05 / 0.14
Shares Outstanding	349,226,509
Market Capitalisation	~A\$20M
Debt (31 Dec 2023)	<i>Nil</i>

SUBSTANTIAL SHAREHOLDERS

Shareholder	%
Tenmile	6.8%
Top 20	56.3%



For personal use only

WORLD-CLASS BOARD AND MANAGEMENT TEAM

Founded and scaled innovative clinical services; commercialised novel drug treatments



Greg Hutchinson
Non-Executive Chairman

- **Health Service Expansion:** Spearheads growth and innovation as CEO Sonic HealthPlus and through 5D Clinics; leads 40+ clinics
- **Strategic Vision:** Influential in Australia's health sector, aligning with mission to expand and innovate mental health treatment services



Prof Sir John Tooke
Non-Executive Director

- **Clinical Leadership:** Former President of the Academy of Medical Sciences, recognised for innovative clinical service design and policy
- **Global Health Payer Expertise:** Influential roles at BUPA and past advisor to Google DeepMind



Dr Karen Smith
Non-Executive Director

- **Biopharma Authority:** 100+ clinical trials and 20+ regulatory approvals
- **Strategic Growth:** Former Chief Medical Officer and Global Head of R&D at Jazz Pharma; drove growth through acquisitions & partnerships



Dr Mohit Kaushal
Non-Executive Director

- **Health IT Strategist:** Key role in Oak Street Health's \$10.6B acquisition by CVS Health; experienced driving growth in tech-centric organisations
- **Health Policy Expert:** Served in Obama administration's Health IT task force; Adjunct Professor at Stanford





Dr Michael Winlo
Managing Director

- **Clinical Data Expertise:** Ex-Palantir healthcare lead, merging Medical Doctor and Stanford MBA credentials to drive health innovation
- **Startup Scaling:** Utilising digital technology, frontline medical experience and business network to drive growth



emyria — OUR 12m ROADMAP —→

For personal use only

#	PROGRAM	MILESTONE 1	MILESTONE 2
1	Launch new service 	 Emyria psychiatrists obtain Authorised Prescriber status	Provide full treatment for first 20 patients
2	Scale service nationally	Commence service in another AU state (via acquisition or licence)	Treat first 20 patients in another AU state
3	Launch second new service for depression	Obtain Authorised Prescriber status for second service	Treat first 5 patients with new service
4	Engage Payers	Secure a major payer partnership	Secure second major Payer
5	Advance drug development programs	Receive Clear Search Report from international patent examiner	Secure granted patents in national phase

For personal use only

CONTACT INFORMATION

Michael Winlo	mwinlo@emyria.com
Investors	investors@emyria.com
Media	media@emyria.com
General	info@emyria.com

INVESTOR HUB:

<https://investorhub.emyria.com/>

